Cancer Specialty
Conference Coverage
- ASCO
- AACR 2024
- ASCO GI 2024
- ASH 2023
- SABCS 2023
- MOASC
- ASCO 2023

Advertisement

X (Twitter) LinkedIn Facebook

X (Twitter) LinkedIn Facebook

Cancer Specialty
Conference Coverage
- ASCO
- AACR 2024
- ASCO GI 2024
- ASH 2023
- SABCS 2023
- MOASC
- ASCO 2023

Home » KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy #ASH19

Non-Hodgkin Lymphoma

KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy #ASH19

By EditorDecember 16, 2019No Comments1 Min Read

Twitter LinkedIn Facebook Email

Share

Twitter LinkedIn Facebook Email

Brian Hill, MD of Cleveland Clinic @ClevelandClinic discusses KTE-X19

Follow on X (Twitter) Follow on LinkedIn Follow on Facebook Follow on Google News

Share. Twitter LinkedIn Facebook Email

Related Posts

Brentuximab v. Nivolumab cHL SWOG S1826 [Slides] Brem, MD – MOASC

Non-Hodgkin Lymphoma 4 Mins Read

Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL

Non-Hodgkin Lymphoma 9 Mins Read

Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL

Non-Hodgkin Lymphoma 9 Mins Read

Advertisement Sidebar

Recent Posts

BRCA Carriers Slicing Breast Cancer Odds: Does Surgery Lead to Longevity Leaps?
Palbociclib (IBRANCE) Revs Up Metastatic Breast Cancer in PATINA Results
Atezolizumab Stumbles in Triple Negative Breast Cancer Study: SABCS 2024 Results with Charles Geyer
Metastatic Breast Cancer: Trastuzumab (Herceptin) Factors for Long-Term Remission in HER2 negative
Breast Cancer New Nemeses: CDK4/6 Inhibitors Rave Against Recurrence, But Have They Crashed the EBC Party in NATALEE & monarchE’s Real-World Dance-Off?

Connect With Us on Social

Facebook
Twitter
LinkedIn

X (Twitter) LinkedIn Facebook

© 2024 Copyright Protected Medicus Networks, Inc..

Type above and press Enter to search. Press Esc to cancel.